Analysts stay bullish on Sun Pharma, raise targets
“A pipeline of four products at various stages of clinical trials should sustain healthy momentum in its speciality business over the medium-to-long term. The expansion of its field force is on track for the India business and Sun Pharma should continue to see market share gains,” said CLSA.
